# Citations for Research Query

**Query:** # Disease Pathophysiology Research Template

## Target Disease
- **Disease Name:** Chronic Myeloid Leukemia, BCR-ABL1 Positive
- **MONDO ID:**  (if available)
- **Category:** 

## Research Objectives

Please provide a comprehensive research report on the pathophysiology of **Chronic Myeloid Leukemia, BCR-ABL1 Positive**.
Focus on the molecular and cellular mechanisms underlying disease progression.

### Required Information

#### 1. Core Pathophysiology
- What are the primary pathophysiological mechanisms?
- What molecular pathways are dysregulated?
- What cellular processes are affected?

#### 2. Key Molecular Players
- **Genes/Proteins**: Which genes are causally involved or implicated?
- **Chemical Entities**: What metabolites, drugs, or small molecules are relevant?
- **Cell Types**: Which cell types are primarily affected?
- **Anatomical Locations**: Which tissues/organs are involved?

#### 3. Biological Processes (for GO annotation)
- What biological processes (GO terms) are disrupted?
- Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

#### 4. Cellular Components
- Where in the cell do key processes occur?
- Consider: organelles, membrane compartments, extracellular space, etc.

#### 5. Disease Progression
- What is the sequence of events from initial trigger to clinical manifestation?
- Are there distinct stages or phases?

#### 6. Phenotypic Manifestations
- What are the key clinical phenotypes?
- How do they relate to the underlying mechanisms?

### Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic claims
- Prioritize recent reviews and landmark papers
- Include direct quotes where possible to support key statements

### Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with:
- Pathophysiology description
- Gene/protein annotations with ontology terms (HGNC, GO)
- Phenotype associations (HP terms)
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Evidence items with PMIDs

**Provider:** falcon
**Generated:** 2026-01-24T18:55:06.842924

1. sicuranza2025thebiologyof pages 1-2
2. alqahtani2025potentialsignalingpathways pages 5-6
3. patterson2023thebonemarrow pages 1-2
4. dolinska2023characterizationofthe pages 14-26
5. pratiwi2025geneticprofilingof pages 23-24
6. rinaldi2023chronicmyeloidleukemia pages 2-4
7. rinaldi2023chronicmyeloidleukemia pages 13-14
8. pratiwi2025geneticprofilingof pages 24-25
9. lagana2025treatmentfreeremission pages 1-2
10. zheng2024treatmentfreeremissionafter pages 1-3
11. patterson2023thebonemarrow pages 2-5
12. patterson2023thebonemarrow pages 5-6
13. zheng2024treatmentfreeremissionafter pages 8-12
14. rinaldi2023chronicmyeloidleukemia pages 8-9
15. zheng2024treatmentfreeremissionafter pages 12-13
16. https://doi.org/10.3389/fonc.2025.1546813
17. https://doi.org/10.3389/fphar.2025.1615770
18. https://doi.org/10.1007/s11899-023-00688-6
19. https://doi.org/10.1182/blood.2022016896
20. https://doi.org/10.1182/blood.2022016896;
21. https://doi.org/10.1038/s41467-023-40222-z;
22. https://doi.org/10.1007/s11899-023-00688-6;
23. https://doi.org/10.2147/jbm.s382090;
24. https://doi.org/10.3390/hematolrep17020018;
25. https://doi.org/10.1038/s41375-025-02664-w;
26. https://doi.org/10.3390/hematolrep17020018
27. https://doi.org/10.31640/ls-2025-4-29
28. https://doi.org/10.1007/s12672-024-01444-9
29. https://doi.org/10.1111/ejh.70006
30. https://doi.org/10.1038/s41467-023-40222-z
31. https://doi.org/10.1038/s41375-025-02664-w
32. https://doi.org/10.1007/s12672-024-01444-9;
33. https://doi.org/10.1111/ejh.70006;
34. https://doi.org/10.1182/blood.2022016896,
35. https://doi.org/10.2147/jbm.s382090,
36. https://doi.org/10.1007/s11899-023-00688-6,
37. https://doi.org/10.1007/s12672-024-01444-9,
38. https://doi.org/10.3389/fonc.2025.1546813,
39. https://doi.org/10.3389/fphar.2025.1615770,
40. https://doi.org/10.3390/hematolrep17020018,
41. https://doi.org/10.31640/ls-2025-4-29,
42. https://doi.org/10.1111/ejh.70006,